This review summarizes recent developments and therapeutic applications of anticoagulants, antiplatelets, and thrombolytics for venous thromboembolism.
Updates antithrombotic options in VTE; extends prior syntheses but leaves optimal regimens open for prospective trials.
Venous thromboembolic diseases are the major concern of rising cost of healthcare and are commonest health problem across the globe. Both genetic and acquired risk factors are believed to be strongly linked with these diseases. Commonly encountered problems to the therapy include dose fixing and routine monitoring, yet some serious problems of bleeding also necessitate the immediate need to develop new agents. The review is primarily concerned with the new developments in the treatment of thromboembolic diseases. Therapeutic applications of anticoagulants, antiplatelets, and thrombolytics have been discussed in enough detail.
No takes yet. Share an insight, caveat, or question.
Agrawal et al. (2007) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: